JP2015500853A - 即時放出マルチユニットペレットシステム - Google Patents

即時放出マルチユニットペレットシステム Download PDF

Info

Publication number
JP2015500853A
JP2015500853A JP2014547894A JP2014547894A JP2015500853A JP 2015500853 A JP2015500853 A JP 2015500853A JP 2014547894 A JP2014547894 A JP 2014547894A JP 2014547894 A JP2014547894 A JP 2014547894A JP 2015500853 A JP2015500853 A JP 2015500853A
Authority
JP
Japan
Prior art keywords
tablet
mups
pharmaceutically acceptable
active substance
pellet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014547894A
Other languages
English (en)
Japanese (ja)
Inventor
カール ゲルハルト ワグナー
カール ゲルハルト ワグナー
ベック　ゲオルク
ゲオルク ベック
グイド ラトケ
グイド ラトケ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2015500853A publication Critical patent/JP2015500853A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014547894A 2011-12-22 2012-12-17 即時放出マルチユニットペレットシステム Pending JP2015500853A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11195261 2011-12-22
EP11195261.0 2011-12-22
PCT/EP2012/075808 WO2013092497A1 (en) 2011-12-22 2012-12-17 Immediate release multi unit pellet system

Publications (1)

Publication Number Publication Date
JP2015500853A true JP2015500853A (ja) 2015-01-08

Family

ID=47469977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014547894A Pending JP2015500853A (ja) 2011-12-22 2012-12-17 即時放出マルチユニットペレットシステム

Country Status (13)

Country Link
US (1) US20130183384A1 (es)
EP (1) EP2793864A1 (es)
JP (1) JP2015500853A (es)
KR (1) KR20140107302A (es)
CN (1) CN103998024A (es)
AU (1) AU2012357956A1 (es)
BR (1) BR112014014795A2 (es)
CA (1) CA2860098A1 (es)
EA (1) EA201400737A1 (es)
IL (1) IL232371A0 (es)
MX (1) MX2014007331A (es)
PH (1) PH12014501408A1 (es)
WO (1) WO2013092497A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104042588B (zh) * 2014-06-17 2016-05-11 浙江京新药业股份有限公司 含甲磺酸达比加群酯的多层片剂
CN104644583A (zh) * 2014-12-25 2015-05-27 青岛黄海制药有限责任公司 一种含达比加群酯的多单元微丸片剂及其制备
WO2016142821A2 (en) * 2015-03-09 2016-09-15 Alphamed Formulations Pvt. Ltd Compositions containing a thrombin inhibitor
WO2016162754A1 (en) 2015-04-07 2016-10-13 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions for minocycline
HUE047477T2 (hu) 2015-06-04 2020-04-28 Pfizer Palbociclib szilárd dózisformái
HUE040694T2 (hu) 2016-01-28 2019-03-28 G L Pharma Gmbh Folsav/vas-készítmény stabilizált kiszerelése
EP3199167A1 (de) 2016-01-28 2017-08-02 G.L. Pharma GmbH Arzneimittel zur behandlung von eisenmangelzuständen mit folsäuredefizit
CN106727414B (zh) * 2016-12-27 2019-06-07 哈药集团技术中心 一种甲磺酸达比加群酯微丸及制备方法
CN111840245B (zh) * 2019-04-28 2023-07-18 成都倍特药业股份有限公司 一种达比加群酯药物组合物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526738A (ja) * 2002-03-07 2005-09-08 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 低溶解度の薬物を経口投与するための投与剤形
JP2007056018A (ja) * 2002-03-07 2007-03-08 Boehringer Ingelheim Pharma Gmbh & Co Kg ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステル又はその塩を含む経口投与用医薬組成物
WO2007086692A1 (en) * 2006-01-27 2007-08-02 Cj Cheiljedang Corporation Multiple unit type sustained release oral formulation and process for the preparation thereof
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
WO2010007016A1 (en) * 2008-07-14 2010-01-21 Boehringer Ingelheim International Gmbh Method for manufacturing medicinal compounds containing dabigatran

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
CN101980697A (zh) 2008-03-28 2011-02-23 贝林格尔.英格海姆国际有限公司 制备口服给药的达比加群制剂的方法
US8962574B2 (en) * 2008-11-11 2015-02-24 Boehringer Ingelheim International Gmbh Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
PT2736497T (pt) * 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente a adulteração proporcionando libertação imediata de fármaco

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526738A (ja) * 2002-03-07 2005-09-08 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 低溶解度の薬物を経口投与するための投与剤形
JP2007056018A (ja) * 2002-03-07 2007-03-08 Boehringer Ingelheim Pharma Gmbh & Co Kg ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステル又はその塩を含む経口投与用医薬組成物
WO2007086692A1 (en) * 2006-01-27 2007-08-02 Cj Cheiljedang Corporation Multiple unit type sustained release oral formulation and process for the preparation thereof
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
WO2010007016A1 (en) * 2008-07-14 2010-01-21 Boehringer Ingelheim International Gmbh Method for manufacturing medicinal compounds containing dabigatran

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6015021306; Ｍ．　Ｅ．　Ｂｈａｄ　ｅｔ　ａｌ．: 'ＭＵＰＳ　Ｔａｂｌｅｔｓ　-　Ａ　Ｂｒｉｅｆ　Ｒｅｖｉｅｗ' Ｉｎｔｅｒｎａｔｉｏｎａｌ　Ｊｏｕｒｎａｌ　ｏｆ　ＰｈａｒｍＴｅｃｈ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．２，　Ｎｏ．１, 201003, ８４７-８５５ *
JPN6015021307; Ｂｒａｎｋａ　ＩＶＩＣ　ｅｔ　ａｌ．: 'Ｅｖａｌｕａｔｉｏｎ　ｏｆ　Ｄｉｃｌｏｆｅｎａｃ　Ｓｏｄｉｕｍ　Ｒｅｌｅａｓｅ　ｆｒｏｍ　Ｍａｔｒｉｘ　Ｐｅｌｌｅｔｓ　Ｃｏｍｐｒｅｓｓｅｄ　ｉｎｔｏ　ＭＵＰＳ　Ｔａｂｌｅｔｓ' ＹＡＫＵＧＡＫＵ　ＺＡＳＳＨＩ Ｖｏｌ．１２９，　Ｎｏ．１１, 20090818, １３７５-１３８４ *
JPN6015021308; ＪＥＲＯＭＥ　ＡＵＢＥＲＴ　ｅｔ　ａｌ．: 'ＯＭＥＰＲＡＺＯＬＥ　ＭＵＰＳ：ＡＮ　ＡＤＶＡＮＣＥＤ　ＦＯＲＭＵＬＡＴＩＯＮ　ＯＦＦＥＲＩＮＧ　ＦＬＥＸＩＢＩＬＩＴＹ　ＡＮＤ　ＰＲＥＤＩＣＴＡＢＩＬＩＴＹ　ＦＯＲ　ＳＥＬＦ　ＭＥＤＩＣＡＴＩＯＮ' ＳｅｌｆＣａｒｅ Ｖｏｌ．２，　Ｓ１, 201103, １-１４ *
JPN6015021310; Ｋａｒｌ　Ｇ．　Ｗａｇｎｅｒ　ｅｔ　ａｌ．: 'Ｉｎｖｅｓｔｉｇａｔｉｏｎ　ｏｆ　ｔｈｅ　ｐｅｌｌｅｔ-ｄｉｓｔｒｉｂｕｔｉｏｎ　ｉｎ　ｓｉｎｇｌｅ　ｔａｂｌｅｔｓ　ｖｉａ　ｉｍａｇｅ　ａｎａｌｙｓｉｓ' Ｅｕｒｏｐｅａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｐｈａｒｍａｃｅｕｔｉｃｓ　ａｎｄ　Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃｓ Ｖｏｌ．４７, 1999, ７９-８５ *
JPN6015021312; Ｂｒａｎｋａ　Ｉｖｉｃ　ｅｔ　ａｌ．: 'Ｏｐｔｉｍｉｚａｔｉｏｎ　ｏｆ　Ｄｒｕｇ　Ｒｅｌｅａｓｅ　ｆｒｏｍ　Ｃｏｍｐｒｅｓｓｅｄ　Ｍｕｌｔｉ　Ｕｎｉｔ　Ｐａｒｔｉｃｌｅ　Ｓｙｓｔｅｍ（ＭＵＰＳ）　Ｕｓｉｎｇ　Ｇｅｎｅｒａｌｉｚｅｄ　Ｒｅｇｒ' Ａｒｃｈ　Ｐｈａｒｍ　Ｒｅｓ Ｖｏｌ．３３，　Ｎｏ．１, 20091011, １０３-１１３ *
JPN6015021315; Ｓｈａｊａｈａｎ　Ａｂｄｕｌ　ｅｔ　ａｌ．: 'Ａ　ｆｌｅｘｉｂｌｅ　ｔｅｃｈｎｏｌｏｇｙ　ｆｏｒ　ｍｏｄｉｆｉｅｄ-ｒｅｌｅａｓｅ　ｄｒｕｇｓ：　Ｍｕｌｔｉｐｌｅ-ｕｎｉｔ　ｐｅｌｌｅｔ　ｓｙｓｔｅｍ　（ＭＵＰＳ）' Ｊｏｕｒｎａｌ　ｏｆ　Ｃｏｎｔｒｏｌｌｅｄ　Ｒｅｌｅａｓｅ Ｖｏｌ．１４７, 20100519, ２-１６ *

Also Published As

Publication number Publication date
CA2860098A1 (en) 2013-06-27
MX2014007331A (es) 2014-09-01
US20130183384A1 (en) 2013-07-18
BR112014014795A2 (pt) 2017-06-13
WO2013092497A1 (en) 2013-06-27
KR20140107302A (ko) 2014-09-04
CN103998024A (zh) 2014-08-20
EP2793864A1 (en) 2014-10-29
PH12014501408A1 (en) 2014-09-22
AU2012357956A1 (en) 2014-05-22
EA201400737A1 (ru) 2014-12-30
IL232371A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
JP6934932B2 (ja) アンドロゲン受容体アンタゴニストの固体医薬組成物
JP4758064B2 (ja) 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬
JP2015500853A (ja) 即時放出マルチユニットペレットシステム
KR101005716B1 (ko) ３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태
JP6588915B2 (ja) Ａｚｄ９２９１を含む医薬組成物
WO2012156981A1 (en) Pharmaceutical compositions of lurasidone
US20160151395A9 (en) Tabletting Process
JP2015506337A (ja) 新規配合剤
WO2011102504A1 (ja) 経口用徐放性固形製剤
EP2533766B1 (en) Pharmaceutical mini-tablets for sustained release of flecainide acetate
JP2012516299A (ja) 有機化合物のガレヌス製剤
EP2331084A1 (en) Pharmaceutical compositions comprising amorphous esomeprazole, dosage forms and process thereof
JP2010536798A (ja) 難溶性薬物の生体利用率を制御するための方法及び組成物
MX2013000827A (es) Composicion de tableta de unidad multiple.
US10835497B2 (en) Rivastigmine-containing sustained-release pharmaceutical composition
US20130251793A1 (en) Pharmaceutical composition comprising phentermine and topiramate
WO2006111853A2 (en) Stable solid dosage forms of acid labile drug
CA2547398A1 (en) Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating
US20220218699A1 (en) New Pharmaceutical Formulation
WO2010018593A2 (en) Gastric acid resistant benzimidazole multiple unit tablet composition
US20210106563A1 (en) Pharmaceutical composition comprising eluxadoline, process of preparation and use thereof
AU2005299253B2 (en) Improved tabletting process
EP2236159A2 (en) Modified release dimebolin compositions
EP2363120A1 (en) Combinations of dimebolin and memantine

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150821

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151116